Register
Register
Register

PDC LINE PHARMA

Biotech company/R&D

www.pdc-line-pharma.com/LIEGE, Belgium

About

Sector: Chemicals, Pharmaceuticals and Lifesciences

About PDC*line Pharma

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC_line). PDC_line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC_line Pharma focuses on the development of PDC_lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC_neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised more than €62M in equity and non-dilutive funding. In March 2019, PDC_line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC_lung01 cancer vaccine for lung cancer. The total deal is worth $123M, plus tiered royalties on net sales in Asia.

www.pdc-line-pharma.com

HEALTH SECTOR

Human healthAnimal healthOne health

DATA MANAGEMENT AND ANALYTICS

Data management and analyticsInfectious diseases modelling and epidemiologyHealth economicsPublic healthReal World Data/ AI / Big Data

SUPPLY CHAIN MANAGEMENT AND LOGISTICS

Cold chain managementBiobanking and biospecimen researchSupply chain managementDistribution and logistics

RESEARCH AND DEVELOPMENT

Preclinical researchImmunotherapy developmentCell and Gene therapyVaccine developmentmRNA vaccinesVaccine platformsVaccine adjuvantsVaccine delivery systemsViral vectorsBiomarker discoveryStem cellsTranslational researchInfectious diseases modelling and epidemiologyDiagnostics

INVESTMENT AND BUSINESS DEVELOPMENT

Business development and partnershipsCommunication & HRFinancing, Investment and funding

MANUFACTURING AND PRODUCTION

Bioprocessing and biomanufacturingManufacturing and productionQuality Control and AssuranceVaccine manufacturingTechnology transferFormulation and fill-finish

CLINICAL DEVELOPMENT AND TRIALS

Clinical trialsReal World DataControlled Human Infection Models (CHIM)PharmacovigilancePatient Recruitment

PATIENT ENGAGEMENT AND ADVOCACY

Patient engagementHealth LiteracyPublic health awarenessGlobal vaccine accessPersonalised medicine

THERAPEUTIC AREAS

Infectious diseasesOncologyImmunologyAutoimmune disordersRare diseasesRespiratory diseasesAllergiesCardiovascular diseasesNeurodegenerative diseasesTransplantationMedical devices

DIGITAL HEALTH AND TECHNOLOGY

Digital health toolsNanotechnologyMedical devicesRobotics / AI / Big Data

INTELLECTUAL PROPERTY AND LEGAL SERVICES

Regulatory affairsIntellectual property

Representatives

Eric HALIOUA

CEO

PDC LINE PHARMA

Sebastien Michel

Senior RD Manager

PDC LINE PHARMA